Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05437419 · ClinicalTrials.gov registry record · Phase 1
A Study to Investigate Safety, Tolerability, and PK of Oral Doses of TCK-276 in Patients With Rheumatoid Arthritis
A Phase 1 study of Rheumatoid Arthritis, sponsored by Teijin America.
- Completed
- Registry status
- Phase 1
- Development phase
- 32
- Enrollment target
- 8
- Study locations
NCT05437419: Completed Phase 1 study of Rheumatoid Arthritis, sponsored by Teijin America.
NCT05437419 is a Phase 1 study of Rheumatoid Arthritis that has completed, run by Teijin America. The registered enrollment target is 32 participants, below the 4,690-participant average among 197 other Rheumatoid Arthritis trials with a reported enrollment target (99% lower). The trial reports 8 study locations across 3 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05437419, a Phase 1 study of Rheumatoid Arthritis, has completed, sponsored by Teijin America.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 32 participants
- Enrollment target
- 8
- Study locations
Study Summary
The study is to evaluate the safety, tolerability, and pharmacokinetic (PK) of multiple orally administered TCK-276 in both males and females with Rheumatoid Arthritis (RA).
Primary Outcome
To evaluate the safety and tolerability of multiple oral doses of TCK-276 or placebo in patients with rheumatoid arthritis (RA)
Conditions Studied
Interventions
- DRUG TCK-276
- DRUG TCK-276 Placebo
Study Locations (8)
Florida
- St. Jude Clinical Research, LLC - Doral
- SouthCoast Research Center, Inc - Miami
- Allied Biomedical Research Institute - Miami
- San Marcus Research Clinic, Inc. - Miami Lakes
- Floridian Clinical Research, LLC - Miami Lakes
- Clinical Site Partners, LLC dba CSP Orlando - Winter Park
California
- Orange County Research Center - Tustin
Texas
- SMS Clinical Research, LLC - Mesquite
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 32 participants |
| Start Date | 2022-08-10 |
| Est. Completion | 2023-07-27 |
| Phase | Phase 1 |
What the finished NCT05437419 record still lists
NCT05437419 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 32 participants, a relatively small participant target, below the 4,690-participant average among 197 other Rheumatoid Arthritis trials with a reported enrollment target (99% lower).
The record links to 1 condition, with Rheumatoid Arthritis appearing as the primary indexed condition, and to 2 interventions - of which TCK-276 is the first listed.
NCT05437419 lists 8 locations in 3 states (Florida, California, Texas).
Frequently Asked Questions
What is clinical trial NCT05437419 about?
NCT05437419 is a clinical study titled "A Study to Investigate Safety, Tolerability, and PK of Oral Doses of TCK-276 in Patients With Rheumatoid Arthritis". The study is to evaluate the safety, tolerability, and pharmacokinetic (PK) of multiple orally administered TCK-276 in both males and females with Rheumatoid Arthritis (RA).
What is the current status of trial NCT05437419?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 32 participants. The study started on 2022-08-10. Estimated completion is 2023-07-27.
What conditions does trial NCT05437419 study?
This clinical trial studies the following conditions: Rheumatoid Arthritis.
What interventions are being tested in trial NCT05437419?
The interventions under investigation include: TCK-276 (DRUG), TCK-276 Placebo (DRUG).
Who is sponsoring clinical trial NCT05437419?
This trial is sponsored by Teijin America, which has 3 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05437419 being conducted?
This trial has 8 study locations across California, Florida, Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Rheumatoid Arthritis
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT05437419's enrollment target sits among peer trials
32 156th of 197 higher than 40 of 197 other Rheumatoid Arthritis trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Rheumatoid Arthritis trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Nivolumab in Treating Patients With Autoimmune Disorders and Advanced, Metastatic, or Unresectable Cancer
RECRUITING · Phase 1
-
Study of GS-0151 in Participants With Rheumatoid Arthritis
RECRUITING · Phase 1
-
MAD Study of IA-14069
RECRUITING · Phase 1
-
A Study of AZD0120 in Autoimmune Diseases
RECRUITING · Phase 1
-
Study Evaluating Safety, Tolerability, PK/PD of Surovatamig in Adult RA or SLE Participants
RECRUITING · Phase 1
-
Imaging of Lymphatic Vessels in People with Rheumatoid Arthritis (RA)
RECRUITING · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02445781 · 32 participants · Early Phase 1
Differing Levels of Hypoglycemia
- NCT02792270 · 32 participants · NA
Caloric Restriction In Sarcoma Patients Treated With Pre-Operative RT
- NCT03068910 · 32 participants · Early Phase 1
Hyperandrogenemia and Altered Day-night LH Pulse Patterns
- NCT03208868 · 32 participants · NA
Leucine Enriched Essential Amino Acid Mixture to Reverse Muscle Loss in Cirrhosis
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI